1	The Relationship Between Immune Cells and Heart Failure: A
2	Study Integrating Immune Infiltration Analysis and Bidirectional
3	Mendelian Randomization
4	Yiding Yu <sup>1#</sup> Huajing Yuan <sup>1#</sup> Wenwen Liu <sup>2</sup> Yitao Xue <sup>3</sup> Xiujuan Liu <sup>3</sup> Wangjun Hou <sup>1</sup> Yan
5	Li <sup>3</sup>
6	1. Shandong University of Traditional Chinese Medicine, Jinan 250014, China;
7	2. Traditional Chinese Medicine Hospital of Jimo District, Qingdao 266200, China;
8	3. Affiliated Hospital of Shandong University of Traditional Chinese Medicine,
9	Jinan 250014, China
10	#: These authors contributed to the work equally and should be regarded as co-first
11	authors.
12	Correspondence: Correspondence should be addressed to Wangjun Hou;
13	<u>331438192@qq.com</u> and Yan Li; <u>liyan88130@163.com</u> .
14	
15	
16	Background: In recent years, attempts have been made to employ various
17	immunomodulatory therapies as new treatment strategies for heart failure, yet the
18	outcomes have been disappointing. Consequently, unveiling the complexity and causal
19	relationships of the immune system's role in heart failure has become imperative.
20	Methods: We first determined the levels of immune cells in failing myocardium using
01	five immune infiltration algorithms: Cibersort vCell ssCSEA MCPcounter and

five immune infiltration algorithms: Cibersort, xCell, ssGSEA, MCPcounter, and QuanTIseq. Subsequently, two-sample bidirectional Mendelian Randomization (MR) analysis was conducted between heart failure and 731 immune cell phenotypes using Inverse Variance Weighted (IVW) as the main method, reinforced by MR-Egger, Weighted median, and Weighted mode as secondary analysis methods. Sensitivity analyses were performed to ensure data stability and feasibility.

Results: Immune infiltration analysis revealed changes in the levels of immune cell
 infiltration in failing myocardium, including T cells, Mast cells, B cells, NK cells, and
 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
 macrophages. MR analysis indicated that 19 immune cell phenotypes from 5 cell types

30 were associated with an increased risk of heart failure, while 12 immune cell 31 phenotypes from 6 cell types were associated with a decreased risk, without 32 heterogeneity and pleiotropy. Reverse MR analysis did not support a causal relationship 33 between HF and any of the 731 immune cell phenotypes.

Conclusion: Our study highlights the complex pattern and causal relationship between the immune system and heart failure through immune infiltration and MR analyses. This provides new insights for the exploration of immunocyte therapies for heart failure. KEYWORDS: heart failure; immune cell phenotypes; Mendelian Randomization analysis; immune infiltration analysis; Causally association

39

### 40 **INTRODUCTION**

Cardiovascular diseases are among the leading causes of mortality worldwide, 41 encompassing conditions such as hypertension, arrhythmias, coronary artery disease, 42 heart failure, and other heart-related diseases. Heart failure, in particular, often 43 represents the final stage of most cardiovascular diseases. It generally results from 44 45 structural modifications or functional disorders of the heart, leading to impairments in ventricular filling or ejection capabilities<sup>1</sup>. As the population ages, the survival rates of 46 ischemic heart disease improve, and more effective evidence-based therapies emerge, 47 the prevalence of heart failure continues to rise, affecting over 64 million individuals 48 globally<sup>2</sup>. Despite ongoing efforts to treat and manage heart failure, there has been little 49 reduction in the burden of mortality and hospitalization<sup>3</sup>. Therefore, researching and 50 identifying modifiable risk factors is crucial for the management and prevention of 51 heart failure. 52

Heart failure is a complex clinical syndrome influenced by numerous factors, including cardiomyopathy, activation of the sympathetic nervous system, abnormalities in energy supply, cardiotoxic drugs, loss of cardiomyocytes, dysregulation of calcium handling, and epigenetic mechanisms<sup>4-10</sup>. In addition to these factors, in recent years, there has been an increasing recognition of the role of inflammation and the immune system in the pathophysiology of heart failure. Following myocardial injury or infection, a substantial influx of immune cells is recruited to the heart to clear dead tissues,

eliminate pathogens, and facilitate healing<sup>11</sup>. Different subtypes of immune cells 60 participate in the inflammatory response, repair processes, and cardiac remodeling in 61 their unique ways, influencing the progression of heart failure. M2 macrophages, which 62 exhibit anti-inflammatory functions, are primarily activated by the inflammatory 63 cytokine IL-4. They mainly exert their effects by secreting anti-inflammatory cytokines 64 such as IL-10 to inhibit M1 macrophages, thereby improving the function of the 65 damaged heart and reducing cardiac fibrosis<sup>12</sup>.Depletion of CD8+ T lymphocytes can 66 67 reduce apoptosis within ischemic myocardial tissue, hinder the inflammatory response, limit myocardial damage, and improve cardiac function<sup>13</sup>. CD4+ T cells, on the other 68 hand, can modulate immune responses by secreting cytokines such as interferon-69 gamma (IFN- $\gamma$ ) and tumor necrosis factor-alpha (TNF- $\alpha$ ), which promote inflammation 70 and myocardial damage<sup>14</sup>. B cells are capable of regulating the heart's adaptation to 71 injury and ultimately influence the extent of cardiac functional impairment following 72 damage<sup>15</sup>.Regulatory T cells (Tregs) are beneficial to the heart as they suppress 73 excessive inflammatory responses in the early stages of heart damage and promote 74 75 stable scar formation. However, in chronic heart failure, the phenotype and function of Tregs can shift towards a pro-fibrotic and anti-angiogenic cell type. This functional 76 transformation has rekindled interest<sup>16</sup>. Additionally, various subtypes of immune cells, 77 including neutrophils, dendritic cells, and NK cells, are involved to varying degrees in 78 the development of heart failure<sup>17-19</sup>. Despite mounting evidence indicating a close 79 connection between various subtypes of immune cells and heart failure, the outcomes 80 of attempts at new treatment strategies using immune modulation therapies have been 81 disappointing<sup>20</sup>. Therefore, unraveling the complexity of the role played by the immune 82 83 system in heart failure, as well as its causal relationships, becomes critically important. In this study, we will utilize five immune infiltration algorithms to uncover the quantity 84 of immune and stromal cells within the failing myocardium, illustrating the 85 myocardium's complex landscape of cellular heterogeneity. Moreover, through 86 Mendelian Randomization (MR) analysis, we will examine the intricate causal and 87 reverse causal relationships between 731 immune cell phenotypes of seven types of 88 immune cells and heart failure. Our research aims to shed new light on the role of 89

- immune cells in the pathophysiology of heart failure and contribute to the development 90
- of immunomodulatory therapies. The outline of the design of our study was shown in 91
- 92 Figure 1.



# **Immunocyte Phenotype**

93

94 Figure 1: The study design.

95

#### **MATERIALS AND METHODS** 96

**Immune Infiltration Analysis** 97

To portray the intricate cell heterogeneity landscape of failing myocardium, we employ 98 five immune infiltration algorithms: Cibersort, xCell, ssGSEA, MCPcounter, and 99 QuanTIseq. The dataset we use is GSE57338, which consists of left ventricular 100 myocardial samples from 95 patients with ischemic heart failure and 136 normal 101 individuals. It represents the largest dataset of myocardial samples from heart failure 102 patients currently available<sup>21</sup>. The Cibersort algorithm performs deconvolution analysis 103 based on the principle of linear support vector regression, cataloging gene expression 104 profiles of 22 types of immune cells. This includes seven types of T cells, naive and 105 memory B cells, plasma cells, NK cells, and myeloid subsets<sup>22</sup>. The xCell algorithm 106 employs ssGSEA to calculate enrichment scores for each cell type signature, enabling 107 the assessment of infiltration levels for up to 64 cell types. This encompasses various 108

adaptive and innate immune cells, hematopoietic stem cells, epithelial cells, and 109 extracellular matrix cells<sup>23</sup>. The ssGSEA algorithm calculates immune cell infiltration 110 based on markers for 24 types of immune cells provided by Bindea<sup>24</sup>. The MCPcounter 111 algorithm uses a linear model to translate the expression levels of immune-related genes 112 into the abundance of eight immune cells and two stromal cells, including T cells, CD8+ 113 T cells, cytotoxic lymphocytes, NK cells, B lymphocytes, monocytes, myeloid dendritic 114 cells, neutrophils, as well as endothelial cells and fibroblasts<sup>25</sup>. The quanTIseq method 115 utilizes a deconvolution algorithm to predict the composition of various types of 116 immune cells within a sample, including 10 immune cell types such as B cells, 117 Monocytes, Neutrophils, Natural killer (NK) cells, and Non-regulatory CD4+ T cells<sup>26</sup>. 118 Cell distribution differences between the heart failure group and the normal group are 119 compared using the t-test, with the threshold set at an adjusted p-value of less than 0.05. 120

121

# 122 MR Study design

In our study, we evaluated the causal relationships between 731 immune cell 123 124 phenotypes (grouped into 7 categories) and heart failure using bidirectional two-sample Mendelian Randomization (MR) analysis. Our research adheres to the three core 125 assumptions of MR analysis: 1. Genetic variants must be strongly associated with the 126 exposure. 2. Genetic variants are uncorrelated with potential confounding factors. 3. 127 Genetic variants should only influence the outcome through the exposure and not 128 through other pathways<sup>27</sup>. All data utilized in this study are publicly available and have 129 been obtained with the consent of the relevant participants and ethical approval, thus 130 institutional review board ethical approval was not required for this research. 131

132

## 133 Exposure and Outcome Data Acquisition

The GWAS catalog (GCST90001391 to GCST90002121) provides a summary of GWAS statistical data for each immunological trait<sup>28</sup>. It encompasses integrated data collected from 3,757 individuals of European ancestry, covering 731 immune phenotypes. As for the outcomes, we selected heart failure data from the HERMES consortium, which includes 47,309 heart failure patients and 930,014 controls<sup>29</sup>.

139

## 140 IVs selection

During the selection process for SNPs, we encountered challenges in identifying 141 142 effective SNPs due to the stringent genome-wide significance threshold (P < 5E-8) applied in our GWAS screening. Consequently, we ultimately opted for a threshold 143 where SNP selection satisfied  $P < 1E-5^{30}$ . To prevent linkage disequilibrium (LD) from 144 affecting the analysis results, we set the LD threshold parameter r to 0.001 and used a 145 distance of 10,000 Kb for SNP analysis. Subsequently, we used the PhenoScanner V2 146 database, a human genotype-phenotype association repository, to further verify the 147 148 inclusion of SNP loci and to check for any other potential confounding variables 149 associated with the included SNP loci. Lastly, to assess whether the included SNPs were affected by weak instrumental variables, we excluded values with an F-statistic greater 150 than 10 (calculated using the formula  $F = \beta^2 / SE^2$ , where  $\beta$  represents the allele 151 effect size, and SE is the standard error). If the F-statistic for SNPs is less than 10, it 152 153 indicates the possibility of a weak instrument variable bias with those SNPs, and therefore, they are excluded to avoid affecting the results. Subsequently, we extract 154 outcome information through the IEU OpenGWAS database and ascertain the 155 relationships among SNPs that meet the assumed criteria from the results. By merging 156 the exposure data set with the generated data set and removing duplicate sequences, we 157 obtain eligible instrumental variables (IVs) that meet the standards for further analysis 158 to establish genetic associations. 159

160

161 Statistical analysis

In our study, Mendelian Randomization (MR) analysis was conducted using the TwoSampleMR and MR-PRESSO packages within the R software, version 4.2.0. In our primary analysis, the Inverse Variance Weighted (IVW) model was applied to assess the causal relationship between each immune cell phenotype and the risk of heart failure <sup>31</sup>. The characteristic of the IVW method is that it does not consider the presence of an intercept and uses the inverse of the final variance (the square of standard error) as the

weight for fitting. When using IVW to explore causal relationships, there may be other 168 factors affecting the bias estimation of genetic diversity and causal effects. MR-Egger 169 regression can detect horizontal pleiotropy through the p-value of the intercept. The 170 principle is to check whether the outcome effect is zero when the instrumental variable 171 effect is zero (i.e., whether the intercept is zero). If the intercept is not zero, it indicates 172 the existence of horizontal pleiotropy, which implies that the outcome exists even 173 without exposure<sup>32</sup>. The MR-PRESSO method is capable of detecting outlier SNPs and, 174 assuming that the SNPs utilized are valid, provides a causal estimate after the potential 175 outliers are removed<sup>33</sup>. Due to the diversity of study subjects and experimental 176 conditions, two-sample Mendelian Randomization (MR) analysis may exhibit 177 heterogeneity, leading to a potential bias in the estimation of causal effects. We 178 primarily assess heterogeneity using Cochran's Q statistic, with a p-value less than 0.05 179 indicating significant heterogeneity. When using the random-effects IVW as the 180 primary outcome measure, heterogeneity is considered acceptable. If the p-value is 181 greater than 0.05 in the test, there is no evidence of heterogeneity among the included 182 183 instrumental variables (IVs), meaning that the impact of heterogeneity on the causal effect estimation can be ignored. Finally, to evaluate the influence of individual SNPs 184 on the overall estimate, a "leave-one-out" analysis is conducted by sequentially 185 excluding each SNP from the analysis. The leave-one-out sensitivity test calculates the 186 MR results of the remaining IVs after each IV is removed one by one. If the MR results 187 estimated by the other IVs differ significantly from the overall result after the exclusion 188 of a particular IV, this indicates that the MR results are sensitive to that IV. If there is 189 no significant change in the overall results, the results are considered reliable. All results 190 191 are presented as odds ratios (OR) with 95% confidence intervals (CI), and when p<0.05, the results are considered to be statistically significant. 192

193

#### 194 **RESULTS**

195 Immune Infiltration Analysis of Myocardium

196 We conducted an immune infiltration analysis on the dataset GSE57338 utilizing five 197 immunoinfiltration algorithms: Cibersort, xCell, ssGSEA, MCPcounter, and

QuanTIseq. According to the Cibersort algorithm, differences were observed in 6 immune cell types. The xCell algorithm indicated differences in 24 cell types. The ssGSEA algorithm revealed discrepancies in 15 immune cell types. The MCPcounter algorithm showed variances in 2 immune cells and 1 stromal cell type. The QuanTIseq algorithm demonstrated differences in 6 immune cell types. The results of the analysis and cell expression are displayed in Figure 2.



204

Figure 6: Immune cell infiltration analysis between HF and control. (A) Result of
Cibersort algorithm. (B) Result of MCPcounter algorithm. (C) Result of QuanTIseq
algorithm. (D) Result of ssGSEA algorithm. (E) Result of xCell algorithm.

208

## 209 Effect of Immunocyte on HF

We conducted instrumental variable (IV) selection on GWAS data for 731 immune cell 210 phenotypes, with all IVs having F values greater than 10, indicating no presence of 211 weak instrument bias. The results from the Inverse Variance Weighted (IVW) method 212 predicting genetic instruments for immune cell phenotypes with causal relationships to 213 heart failure are shown in Figure 3. Our analysis indicates that 19 immune cell 214 215 phenotypes across 5 immune cell groups are associated with an increased risk of heart failure (OR>1, P<0.05). Specifically, B cell phenotypes include: CD19 on IgD+, IgD+ 216 AC, IgD on IgD+ CD38dim, CD27 on IgD- CD38dim, IgD on IgD+ CD24+, CD27 on 217 IgD- CD38-, IgD+ CD38br AC, CD38 on IgD+ CD38br, CD19 on IgD+ CD38br, Sw 218 mem %lymphocyte, and BAFF-R on IgD- CD38dim. cDC phenotype: CCR2 on 219 CD62L+ myeloid DC. Myeloid cell phenotype: CD45 on lymphocyte. TBNK 220 phenotype: TCRgd %lymphocyte. Treg phenotypes include: CD28+ CD45RA+ 221 CD8br %T cell, CD28+ CD45RA+ CD8br AC, CD39+ CD8br %CD8br, CD28-222 223 CD127- CD25++ CD8br %CD8br, and CD28- CD127- CD25++ CD8br %T cell. There are 12 immune cell phenotypes across 6 immune cell groups that are associated with a 224 decreased risk of heart failure (OR<1, P<0.05). Specifically, B cell phenotypes include: 225 CD20 on IgD+ CD38br, Unsw Mem %lymphocyte, BAFF-R on IgD+ CD38br, and 226 CD20 on IgD- CD38dim. cDC phenotype: CD62L- DC %DC. Maturation stages of T 227 cell phenotype: HVEM on TD CD4+. Myeloid cell phenotype: CD11b on CD14+ 228 monocyte. TBNK phenotypes include: HLA DR++ monocyte %leukocyte, SSC-A on 229 HLA DR+ NK, SSC-A on CD14+ monocyte, and CD45 on CD8br. Treg phenotype: 230 231 Activated Treg AC. Results for all analytical methods are provided in Supplementary File 1. 232

Exposure	No.of SNP	OR(95% CI)		or	Р
IgD+ CD38+ B cell Absolute Count	23	1.03 (1.01 to 1.05)		1.0301937	0.003
IgD+ B cell Absolute Count	14	1.02 (1.00 to 1.04)	<b>→</b> →+	1.0182280	0.033
Unswitched memory B cell %lymphocyte	17	0.96 (0.93 to 1.00)	H-0-1	0.9637570	0.032
Switched memory B cell %lymphocyte	14	1.04 (1.01 to 1.07)		1.0369716	0.011
CD62L- Dendritic Cell %Dendritic Cell	20	0.99 (0.98 to 1.00)	Hel	0.9850566	0.003
HLA DR++ monocyte %leukocyte	4	0.93 (0.87 to 0.99)	<b>←●</b> ──1	0.9252151	0.023
Activated CD4 regulatory T cell Absolute Count	11	0.98 (0.97 to 1.00)	Hert	0.9810853	0.014
TCRgd T cell %lymphocyte	15	1.02 (1.00 to 1.04)		1.0229754	0.018
CD39+ CD8+ T cell %CD8+ T cell	19	1.03 (1.01 to 1.05)		1.0300797	0.004
CD28-CD127-CD25++CD8+T cell %T cell	11	1.04 (1.01 to 1.07)		1.0388585	0.004
CD28- CD127- CD25++ CD8+ T cell %CD8+ T cell	. 12	1.04 (1.01 to 1.06)	<b>H-0-1</b>	1.0381481	0.004
CD28+ CD45RA+ CD8+ T cell %T cell	63	1.00 (1.00 to 1.01)		1.0031683	0.005
CD28+ CD45RA+ CD8+ T cell Absolute Count	38	1.00 (1.00 to 1.01)	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1.0042138	0.034
BAFF-R on IgD+ CD38+ B cell	20	0.98 (0.97 to 1.00)	H=-1	0.9848356	0.037
BAFF-R on IgD- CD38dim B cell	4	1.05 (1.01 to 1.08)		1.0451957	0.017
CD19 on IgD+ CD38+ B cell	15	1.03 (1.00 to 1.06)		1.0321806	0.043
CD19 on IgD+ B cell	20	1.02 (1.00 to 1.03)	) <del></del>	1.0168414	0.025
CD20 on IgD+ CD38+ B cell	20	0.98 (0.96 to 1.00)	H-BH	0.9764478	0.022
CD20 on IgD- CD38dim B cell	26	0.99 (0.98 to 1.00)	He	0.9910694	0.040
CD27 on IgD- CD38- B cell	24	1.03 (1.01 to 1.05)		1.0276504	0.007
CD27 on IgD- CD38dim B cell	24	1.02 (1.00 to 1.04)	<b>}</b>	1.0217697	0.021
CD38 on IgD+ CD38+ B cell	15	1.03 (1.00 to 1.05)		1.0276529	0.040
IgD on IgD+ CD24+ B cell	20	1.02 (1.00 to 1.05)	>	1.0248458	0.030
IgD on IgD+ CD38dim B cell	17	1.02 (1.00 to 1.04)		1.0194439	0.042
HVEM on Terminally Differentiated CD4+ T cell	19	0.98 (0.97 to 1.00)	H++	0.9831819	0.049
CD45 on CD8+ T cell	17	0.99 (0.98 to 1.00)	Hel	0.9900776	0.047
CCR2 on CD62L+ myeloid Dendritic Cell	13	1.04 (1.01 to 1.07)	¦⊷⊷+	1.0353869	0.021
CD45 on lymphocyte	12	1.04 (1.01 to 1.07)	<b>⊢</b> •→	1.0379188	0.006
SSC-A on CD14+ monocyte	19	0.98 (0.96 to 1.00)	H	0.9794735	0.046
SSC-A on HLA DR+ Natural Killer	18	0.98 (0.97 to 1.00)		0.9829302	0.020
CD11b on CD14+ monocyte	19	0.98 (0.97 to 1.00)	Heri	0.9840893	0.016
		0	9 1	11	

233

234 *Figure 3: Associations between immune cell phenotypes and risk of heart failure.* 

235

# 236 Sensitivity Analysis of the Effect of Immunocyte on HF

The sensitivity analysis results indicate that the immune cell phenotypes used for MR 237 analysis in heart failure do not present evidence of heterogeneity (Q test P>0.05), 238 horizontal pleiotropy (MR-Egger intercept method P>0.05), or significant outliers, 239 suggesting that our findings are robust and credible. The "leave-one-out" analysis 240 reveals that sequentially excluding each single nucleotide polymorphism (SNP) yields 241 results from the remaining SNPs' IVW analysis that are consistent with the outcomes 242 obtained when all SNPs are included, therefore indicating that no single SNP has a 243 substantial effect on the estimated causal association. The results of heterogeneity and 244 pleiotropy analysis are shown in Supplementary file 2. 245

246

## 247 Effect of HF on Immunocyte

We performed IV selection on the GWAS data for HF, ensuring that all IVs had an F statistic greater than 10 to avoid weak instrument bias. Unfortunately, our MR analysis did not uncover any causal relationships between HF and the 731 immune cell phenotypes examined. As such, we found no bidirectional causality between immune cell phenotypes and heart failure.

253

## 254 **DISCUSSION**

In our study, we initially employed five different immune infiltration analysis 255 algorithms to assess the complex cellular heterogeneity within the failing myocardium. 256 Despite variations in the underlying logic and weights of the different immune 257 258 infiltration analysis algorithms, all five methods consistently indicated an upregulated expression of T cells or their subgroups in the failing myocardium as compared to 259 normal myocardium. Additionally, at least two of these algorithms support the presence 260 of differences in Mast cells, B cells, NK cells, and macrophages within the failing 261 262 myocardium. Hence, the results of our immune infiltration analysis suggest alterations in certain immune cell levels in the failing myocardium when contrasted with normal 263 myocardium. 264

In order to investigate whether the altered levels of immune cells are causally associated 265 with the onset and progression of HF, we systematically provided genetic support for 266 the causal relationship between 731 immune cell phenotypes across seven groups of 267 immune cells and HF through bidirectional MR analysis. We observed a causal 268 relationship between 31 immune cell phenotypes in B cells, cDC, TBNK, Treg, 269 270 Myeloid cells and Maturation stages of T cells with HF in forward MR. In contrast, in 271 reverse MR, there was no evidence to support a causal relationship between HF and 731 immune cell phenotypes. There was no bidirectional causality between HF and 731 272 immune cell phenotypes. As the results of the reverse MR analysis do not support a 273 causal relationship between HF and immune cells, this suggests that the changes in 274 immune cell levels observed in the failing myocardium are not caused by heart failure 275 itself. Although the reasons for these alterations in immune cell expression are not yet 276

277 clear, they may have an impact on the progression of heart failure.

The results of the immune infiltration analysis indicate an increased expression of T 278 cells and their subgroups in the failing myocardium. However, the MR analysis reveals 279 that the impact of different immune phenotypes within T cell subgroups, such as CD4 280 or CD8, on heart failure is complex, which may account for the discouraging outcomes 281 of immune modulatory therapies. Alba Vilella-Figuerola et al. demonstrated that 282 activated CD45+ T cells were positively correlated with the severity of congestive HF, 283 284 which was consistent with our MR analysis of CD45 on lymphocyte positively correlated with HF<sup>34</sup>. Elisa Martini et al. focused their research on CD45+ cells and 285 found that activated immune cells were strongly associated with HF<sup>35</sup>. Yun-Long Zhang 286 et al. concluded that targeting CD11b was associated with cardiac remodeling and may 287 benefit HF<sup>36</sup>. Animal studies have demonstrated that the systemic activation of induced 288 regulatory T cells can be employed in anti-remodeling therapy for the repair of ischemic 289 tissues<sup>37</sup>. The expression of CD69 on regulatory T cells can also protect against immune 290 injury post-myocardial infarction, thereby preventing heart failure<sup>38</sup>. Furthermore, 291 292 research has indicated that cardiac fibroblasts expressing xenogeneic antigens can be effectively targeted and eliminated through the adoptive transfer of antigen-specific 293 alleviate myocardial fibrosis<sup>39</sup>. Therefore, CD8+ Т cells, which may 294 immunomodulatory therapies that intervene with T cells are promising, but it is 295 important to consider the regulation of specific subgroups<sup>40</sup>. 296

MR results identified 16 immune cell phenotypes in B cells that were significantly 297 associated with HF. B cells are a key part of the organism's immune system, 298 participating in the immune response through the production of antibodies, as well as 299 in regulating the activities of other immune cells<sup>41</sup>. B cells regulate macrophage 300 phenotype in the myocardium and play an important role in maintaining myocardial 301 homeostasis<sup>42</sup>. Several studies have shown that B cells can influence cardiac 302 remodeling and inflammatory responses after myocardial infarction, thereby mediating 303 HF<sup>43,44</sup>. In addition, antibodies may also mediate myocardial injury through 304 complement-associated mechanisms and may interact with cardiomyocytes or other 305 immune cells to affect myocardial function<sup>45-47</sup>. Andrea M. Cordero-Reyes et al. 306

307 concluded that pathways of B cell activation were intimately involved in the 308 progression of  $HF^{48}$ .

MR results identified 5 immune cell phenotypes in TBNK cells that were significantly 309 associated with HF. Existing studies suggest that natural killer (NK) cells contribute to 310 the mitigation of cardiac inflammation and fibrosis by inhibiting the infiltration of 311 eosinophils, thereby exerting an anti-heart failure effect<sup>49</sup>. Additionally, NK cells may 312 offer protective benefits in the aftermath of a heart attack by boosting the expression of 313 314 cardioprotective cytokines, including IL-10, which aids in the remodeling and preservation of left ventricular function<sup>50</sup>. In a contradiction, findings derived from the 315 xCell algorithm indicate a reduction in NK cell expression within failing myocardial 316 tissue, which is at odds with the results yielded by the ssGSEA and QuanTIseq 317 algorithms. This is further complicated by a clinical study involving 82 patients with 318 end-stage heart failure, which revealed that the levels of circulating NK cells in patients 319 were lower compared to healthy individuals<sup>51</sup>. 320

Our study also identified certain immune cell phenotypes that exhibit causal 321 322 relationships with HF, yet to date, there have been no clinical studies or reports on their association with HF. The role of these immune cell phenotypes in the pathogenesis of 323 heart failure holds promise and warrants further investigation. Additionally, our 324 bidirectional Mendelian randomization does not support a causal relationship between 325 HF and 731 immune cell phenotypes. This suggests that certain immune cell 326 phenotypes that could potentially ameliorate or accelerate the course of heart failure are 327 328 not influenced by the progression of the condition.

In this study, we initially confirmed the levels of immune cells in failing myocardium 329 330 using five distinct immune infiltration analysis algorithms. Subsequently, a two-sample bidirectional MR analysis was performed, which allowed for large sample sizes and 331 high statistical efficiency. The conclusions of the MR analysis in this research are based 332 on exploring the causal relationship between the two variables with genetic 333 instrumental variables, and causal inference and result verification were carried out 334 using various MR analysis methods. Therefore, the results are robust and not affected 335 or confounded by pleiotropy at horizontal levels. 336

However, our study should consider some limitations. Firstly, due to the differing logic 337 and weights of the immune infiltration analysis algorithms used, there are 338 inconsistencies in the computed results, which require further experimental support. 339 Secondly, we selected IVs with a P-value threshold of P < 1E-5, therefore, the strength 340 of the associations of these IVs may not be robust, despite allowing for a more 341 comprehensive assessment of the association between immune cell phenotypes and 342 heart failure. Thirdly, as this study is based on a European population, the applicability 343 344 of the results to other ethnic groups remains debatable, limiting the breadth of our results. Additionally, despite multiple sensitivity analyses, the assessment of horizontal 345 pleiotropy remains limited. While statistically it is considered satisfactory to eliminate 346 heterogeneity and horizontal pleiotropy, it cannot be fully guaranteed that such factors 347 are absent in the clinical environment. Finally, comprehensive clinical trials are needed 348 to draw clinical conclusions. Therefore, to elucidate the association and mechanisms 349 between individual immune cell phenotypes and heart failure, we need more extensive 350 GEO and GWAS databases, as well as further analytical methods or experimental 351 352 validations.

353

### 354 CONCLUSION

We determined the levels of immune cells in failing myocardium using five immune infiltration analysis algorithms and demonstrated the causal relationships between various immune cell phenotypes and heart failure through comprehensive bidirectional two-sample MR analysis. This opens new avenues for researchers to explore the biological mechanisms of heart failure. More importantly, it offers innovative perspectives for investigating immunocyte therapies for heart failure, which may aid in the prevention and treatment of heart failure.

362

363

## 364 Acknowledgements

365 Not applicable.

367	CRediT authorship contribution statement
368	Yiding Yu: Conceptualization, Methodology, Validation, Formal analysis,
369	Investigation, Resources, Visualization, Writing – original draft, Writing – review &
370	editing. Huajing Yuan: Methodology, Validation, Formal analysis, Software, Data
371	curation, Writing – original draft. Wenwen Liu: Software, Data curation, Writing –
372	review & editing. Yitao Xue: Supervision, Funding acquisition, Writing – review &
373	editing. Xiujuan Liu: Project administration, Supervision, Writing – review & editing.
374	Wangjun Hou: Project administration, Writing – review & editing, Funding
375	acquisition. Yan Li: Project administration, Writing – review & editing, Funding
376	acquisition.
377	
378	Consent for publication
379	Not applicable.
379 380	Not applicable.
379 380 381	Not applicable. Competing interests
379 380 381 382	Not applicable. Competing interests The authors have no conflict of interest to disclose.
379 380 381 382 383	Not applicable. Competing interests The authors have no conflict of interest to disclose.
<ul> <li>379</li> <li>380</li> <li>381</li> <li>382</li> <li>383</li> <li>384</li> </ul>	Not applicable. Competing interests The authors have no conflict of interest to disclose. Ethics approval and consent to participate
<ul> <li>379</li> <li>380</li> <li>381</li> <li>382</li> <li>383</li> <li>384</li> <li>385</li> </ul>	Not applicable. Competing interests The authors have no conflict of interest to disclose. Ethics approval and consent to participate Not applicable.
<ul> <li>379</li> <li>380</li> <li>381</li> <li>382</li> <li>383</li> <li>384</li> <li>385</li> <li>386</li> </ul>	Not applicable. Competing interests The authors have no conflict of interest to disclose. Ethics approval and consent to participate Not applicable.
<ul> <li>379</li> <li>380</li> <li>381</li> <li>382</li> <li>383</li> <li>384</li> <li>385</li> <li>386</li> <li>387</li> </ul>	Not applicable. Competing interests The authors have no conflict of interest to disclose. Ethics approval and consent to participate Not applicable. Funding
<ul> <li>379</li> <li>380</li> <li>381</li> <li>382</li> <li>383</li> <li>384</li> <li>385</li> <li>386</li> <li>387</li> <li>388</li> </ul>	Not applicable. Competing interests The authors have no conflict of interest to disclose. Ethics approval and consent to participate Not applicable. Funding Our work was supported by the Natural Science Foundation of Shandong Province (CN)

390 Nos. 81774247 and 81804045].

391

## 392 Availability of data and materials

393 Publicly available datasets were analyzed in this study. This data can be found here:

- 394 GSE57338 and GWAS Catalog (https://www.ebi.ac.uk/gwas/downloads/summary-
- 395 statistics)
- 396
- 397
- 398
- 399
- 400

## 401 **REFERENCES**

1. S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, T.G. 402 403 Ganiats, M. Jessup, M.A. Konstam, D.M. Mancini, K. Michl, J.A. Oates, P.S. 404 Rahko, M.A. Silver, L.W. Stevenson, C.W. Yancy, E.M. Antman, S.C. Smith Jr., C.D. Adams, J.L. Anderson, D.P. Faxon, V. Fuster, J.L. Halperin, L.F. Hiratzka, S.A. 405 Hunt, A.K. Jacobs, R. Nishimura, J.P. Ornato, R.L. Page, B. Riegel, Acc/aha 2005 406 guideline update for the diagnosis and management of chronic heart failure in the adult 407 summary article. J. Am. Coll. Cardiol. 46 (2005)1116-1143, 408 https://doi.org/10.1016/j.jacc2005.08023. 409

Savarese, G., Becher, P. M., Lund, L. H., Seferovic, P., Rosano, G. M. C., & Coats,
 A. J. S. (2023). Global burden of heart failure: a comprehensive and updated review of
 epidemiology. Cardiovascular research, 118(17), 3272–3287.
 https://doi.org/10.1093/cvr/cvac013

414 3. Roger V. L. (2021). Epidemiology of Heart Failure: A Contemporary Perspective.

- 415 Circulation research, 128(10), 1421–1434.
- 416 https://doi.org/10.1161/CIRCRESAHA.121.318172
- 417 4. Towbin, J., & Bowles, N. (2002). The failing heart. Nature, 415, 227-233.

418 https://doi.org/10.1038/415227a.

- 419 5. Lymperopoulos, A., Rengo, G., & Koch, W. (2013). Adrenergic Nervous System
- 420 in Heart Failure: Pathophysiology and Therapy. Circulation Research, 113, 739–753.
- 421 https://doi.org/10.1161/CIRCRESAHA.113.300308.
- 422 6. Ventura-clapier, R., Garnier, A., & Veksler, V. (2004). Energy metabolism in heart
- 423 failure. The Journal of Physiology, 555. https://doi.org/10.1113/jphysiol.2003.055095.
- 424 7. Kemp, C., & Conte, J. (2012). The pathophysiology of heart failure..
- 425 Cardiovascular pathology : the official journal of the Society for Cardiovascular
- 426 Pathology, 21 5, 365-71 . https://doi.org/10.1016/j.carpath.2011.11.007.
- 8. Slørdal, L., & Spigset, O. (2006). Heart Failure Induced by Non-Cardiac Drugs.
  Drug Safety, 29, 567-586. https://doi.org/10.2165/00002018-200629070-00003.
- 9. Oka, T., & Komuro, I. (2008). Molecular mechanisms underlying the transition of
  cardiac hypertrophy to heart failure.. Circulation journal : official journal of the
  Japanese Circulation Society, 72 Suppl A, A13-6 . https://doi.org/10.1253/CIRCJ.CJ08-0481.
- 433 10. Papait, R., Greco, C., Kunderfranco, P., Latronico, M., & Condorelli, G. (2013).
- 434 Epigenetics: a new mechanism of regulation of heart failure?. Basic Research in
  435 Cardiology, 108. https://doi.org/10.1007/s00395-013-0361-1.
- 436 11. Swirski, F., & Nahrendorf, M. (2018). Cardioimmunology: the immune system in
- 437 cardiac homeostasis and disease. Nature Reviews Immunology, 18, 733 744.
  438 https://doi.org/10.1038/s41577-018-0065-8.
- 439 12. Peet, C., Ivetic, A., Bromage, D. I., & Shah, A. M. (2020). Cardiac monocytes and
- 440 macrophages after myocardial infarction. Cardiovascular research, 116(6), 1101–1112.
- 441 https://doi.org/10.1093/cvr/cvz336
- 442 13. Santos-Zas, I., Lemarié, J., Zlatanova, I., Cachanado, M., Seghezzi, J. C., Benamer,
- 443 H., Goube, P., Vandestienne, M., Cohen, R., Ezzo, M., Duval, V., Zhang, Y., Su, J. B.,
- 444 Bizé, A., Sambin, L., Bonnin, P., Branchereau, M., Heymes, C., Tanchot, C., Vilar, J., ...
- 445 Ait-Oufella, H. (2021). Cytotoxic CD8+ T cells promote granzyme B-dependent
- 446 adverse post-ischemic cardiac remodeling. Nature communications, 12(1), 1483.
- 447 https://doi.org/10.1038/s41467-021-21737-9

- 448 14. Vdovenko, D., & Eriksson, U. (2018). Regulatory Role of CD4+ T Cells in
- 449 Myocarditis. Journal of immunology research, 2018, 4396351.
  450 https://doi.org/10.1155/2018/4396351
- 451 15. Bermea, K., Bhalodia, A., Huff, A., Rousseau, S., & Adamo, L. (2022). The Role
- 452 of B Cells in Cardiomyopathy and Heart Failure. Current cardiology reports, 24(8),
- 453 935–946. https://doi.org/10.1007/s11886-022-01722-4
- 454 16. Lu, Y., Xia, N., & Cheng, X. (2021). Regulatory T Cells in Chronic Heart Failure.
- 455 Frontiers in immunology, 12, 732794. https://doi.org/10.3389/fimmu.2021.732794
- 456 17. Tang, X., Wang, P., Zhang, R., Watanabe, I., Chang, E., Vinayachandran, V., Nayak,
- 457 L., Lapping, S., Liao, S., Madera, A., Sweet, D. R., Luo, J., Fei, J., Jeong, H. W., Adams,
- 458 R. H., Zhang, T., Liao, X., & Jain, M. K. (2022). KLF2 regulates neutrophil activation
- and thrombosis in cardiac hypertrophy and heart failure progression. The Journal of
  clinical investigation, 132(3), e147191. https://doi.org/10.1172/JCI147191
- 461 18. Saleh, D., Jones, R. T. L., Schroth, S. L., Thorp, E. B., & Feinstein, M. J. (2023).
- 462 Emerging Roles for Dendritic Cells in Heart Failure. Biomolecules, 13(10), 1535.
- 463 https://doi.org/10.3390/biom13101535
- 464 19. Ong, S., Rose, N., & Čiháková, D. (2017). Natural killer cells in inflammatory
  465 heart disease.. Clinical immunology, 175, 26-33 .
  466 https://doi.org/10.1016/j.clim.2016.11.010.
- 467 20. Fildes, J. E., Shaw, S. M., Yonan, N., & Williams, S. G. (2009). The immune system
- and chronic heart failure: is the heart in control?. Journal of the American College of
- 469 Cardiology, 53(12), 1013–1020. https://doi.org/10.1016/j.jacc.2008.11.046
- 470 21. Liu, Y., Morley, M., Brandimarto, J., Hannenhalli, S., Hu, Y., Ashley, E. A., Tang,
- 471 W. H., Moravec, C. S., Margulies, K. B., Cappola, T. P., Li, M., & MAGNet consortium
- 472 (2015). RNA-Seq identifies novel myocardial gene expression signatures of heart
- 473 failure. Genomics, 105(2), 83–89. https://doi.org/10.1016/j.ygeno.2014.12.002
- 474 22. Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang,
- 475 C. D., Diehn, M., & Alizadeh, A. A. (2015). Robust enumeration of cell subsets from
- 476 tissue expression profiles. Nature methods, 12(5), 453-457.
- 477 https://doi.org/10.1038/nmeth.3337

- 478 23. Aran, D., Hu, Z., & Butte, A. J. (2017). xCell: digitally portraying the tissue cellular
  heterogeneity landscape. Genome biology, 18(1), 220. https://doi.org/10.1186/s13059480 017-1349-1
- 481 24. Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C.,
- Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., Bruneval, P., Fridman, W. H.,
  Becker, C., Pagès, F., Speicher, M. R., Trajanoski, Z., & Galon, J. (2013).
- 484 Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape 485 in human cancer. Immunity, 39(4), 782–795.
- 486 https://doi.org/10.1016/j.immuni.2013.10.003
- 487 25. Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves,
- 488 J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., & de Reyniès, A. (2016).
- Estimating the population abundance of tissue-infiltrating immune and stromal cell
  populations using gene expression. Genome biology, 17(1), 218.
  https://doi.org/10.1186/s13059-016-1070-5
- 26. Finotello, F., Mayer, C., Plattner, C., Laschober, G., Rieder, D., Hackl, H., 492 493 Krogsdam, A., Loncova, Z., Posch, W., Wilflingseder, D., Sopper, S., Ijsselsteijn, M., Brouwer, T. P., Johnson, D., Xu, Y., Wang, Y., Sanders, M. E., Estrada, M. V., Ericsson-494 Gonzalez, P., Charoentong, P., ... Trajanoski, Z. (2019). Molecular and 495 pharmacological modulators of the tumor immune contexture revealed by 496 deconvolution of RNA-seq data. Genome medicine, 11(1), 34. 497 https://doi.org/10.1186/s13073-019-0638-6 498
- 27. Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016). Consistent
  Estimation in Mendelian Randomization with Some Invalid Instruments Using a
  Weighted Median Estimator. Genetic epidemiology, 40(4), 304–314.
  https://doi.org/10.1002/gepi.21965
- 503 28. Orrù, V., Steri, M., Sidore, C., Marongiu, M., Serra, V., Olla, S., Sole, G., Lai, S.,
- 504 Dei, M., Mulas, A., Virdis, F., Piras, M. G., Lobina, M., Marongiu, M., Pitzalis, M.,
- 505 Deidda, F., Loizedda, A., Onano, S., Zoledziewska, M., Sawcer, S., ... Cucca, F. (2020).
- 506 Complex genetic signatures in immune cells underlie autoimmunity and inform therapy.
- 507 Nature genetics, 52(10), 1036–1045. https://doi.org/10.1038/s41588-020-0684-4

- 508 29. Shah, S., Henry, A., Roselli, C., Lin, H., Sveinbjörnsson, G., Fatemifar, G.,
- 509 Hedman, Å. K., Wilk, J. B., Morley, M. P., Chaffin, M. D., Helgadottir, A., Verweij, N.,
- 510 Dehghan, A., Almgren, P., Andersson, C., Aragam, K. G., Ärnlöv, J., Backman, J. D.,
- 511 Biggs, M. L., Bloom, H. L., ... Lumbers, R. T. (2020). Genome-wide association and
- 512 Mendelian randomisation analysis provide insights into the pathogenesis of heart
- 513 failure. Nature communications, 11(1), 163. https://doi.org/10.1038/s41467-019-
- 514 13690-5
- 515 30. Li, P., Wang, H., Guo, L., Gou, X., Chen, G., Lin, D., Fan, D., Guo, X., & Liu, Z.
- 516 (2022). Association between gut microbiota and preeclampsia-eclampsia: a two-sample
- 517 Mendelian randomization study. BMC medicine, 20(1), 443.
  518 https://doi.org/10.1186/s12916-022-02657-x
- 519 31. Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin,
- 520 C., Burgess, S., Bowden, J., Langdon, R., Tan, V. Y., Yarmolinsky, J., Shihab, H. A.,
- 521 Timpson, N. J., Evans, D. M., Relton, C., Martin, R. M., Davey Smith, G., Gaunt, T. R.,
- 522 & Haycock, P. C. (2018). The MR-Base platform supports systematic causal inference
- across the human phenome. eLife, 7, e34408. https://doi.org/10.7554/eLife.34408
- 32. Bowden, J., Davey Smith, G., & Burgess, S. (2015). Mendelian randomization with
  invalid instruments: effect estimation and bias detection through Egger regression.
  International journal of epidemiology, 44(2), 512–525.
  https://doi.org/10.1093/ije/dyv080
- 33. Verbanck, M., Chen, C. Y., Neale, B., & Do, R. (2018). Detection of widespread
  horizontal pleiotropy in causal relationships inferred from Mendelian randomization
  between complex traits and diseases. Nature genetics, 50(5), 693–698.
  https://doi.org/10.1038/s41588-018-0099-7
- 34. Vilella-Figuerola A, Padro T, Roig E, Mirabet S, Badimon L. New factors in heart
  failure pathophysiology: Immunity cells release of extracellular vesicles. Front
  Cardiovasc Med (2022) 9: 939625. doi:10.3389/fcvm.2022.939625
- 535 35. Martini E, Kunderfranco P, Peano C, Carullo P, Cremonesi M, Schorn T, et al.
- 536 Single-Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overload-Driven
- Heart Failure Reveals Extent of Immune Activation. Circulation (2019) 140: 2089-107.

## 538 doi:10.1161/CIRCULATIONAHA.119.041694

- 539 36. Zhang YL, Bai J, Yu WJ, Lin QY, Li HH. CD11b mediates hypertensive cardiac
- remodeling by regulating macrophage infiltration and polarization. J Adv Res (2024)
- 541 55: 17-31. doi:10.1016/j.jare.2023.02.010
- 542 37. Choo EH, Lee JH, Park EH, Park HE, Jung NC, Kim TH, Koh YS, Kim E, Seung
- KB, Park C, Hong KS, Kang K, Song JY, Seo HG, Lim DS, Chang K. Infarcted
  Myocardium-Primed Dendritic Cells Improve Remodeling and Cardiac Function After
- 545 Myocardial Infarction by Modulating the Regulatory T Cell and Macrophage
- 546 Polarization. Circulation. 2017 Apr 11;135(15):1444-1457. doi:
  547 10.1161/CIRCULATIONAHA.116.023106.
- 548 38. Blanco-Domínguez R, de la Fuente H, Rodríguez C, Martín-Aguado L, Sánchez-
- 549 Díaz R, Jiménez-Alejandre R, Rodríguez-Arabaolaza I, Curtabbi A, García-Guimaraes
- 550 MM, Vera A, Rivero F, Cuesta J, Jiménez-Borreguero LJ, Cecconi A, Duran-Cambra A,
- 551 Taurón M, Alonso J, Bueno H, Villalba-Orero M, Enríquez JA, Robson SC, Alfonso F,
- 552 Sánchez-Madrid F, Martínez-González J, Martín P. CD69 expression on regulatory T
- cells protects from immune damage after myocardial infarction. J Clin Invest. 2022
- 554 Nov 1;132(21):e152418. doi: 10.1172/JCI152418.
- 39. Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J,
- 556 Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Linares Saldana RA, Bolar NA,
- 557 McDaid K, Assenmacher CA, Smith CL, Wirth D, June CH, Margulies KB, Jain R,
- 558 Puré E, Albelda SM, Epstein JA. Targeting cardiac fibrosis with engineered T cells.
- 559 Nature. 2019 Sep;573(7774):430-433. doi: 10.1038/s41586-019-1546-z.
- 40. Lu Y, Xia N, Cheng X. Regulatory T Cells in Chronic Heart Failure. Front Immunol.
- 561 2021 Sep 22;12:732794. doi: 10.3389/fimmu.2021.732794.
- 562 41. Bermea K, Bhalodia A, Huff A, Rousseau S, Adamo L. The Role of B Cells in
- 563 Cardiomyopathy and Heart Failure. Curr Cardiol Rep (2022) 24: 935-46. 564 doi:10.1007/s11886-022-01722-4
- 42. Rocha-Resende C, Pani F, Adamo L. B cells modulate the expression of MHC-II
- 566 on cardiac CCR2(-) macrophages. J Mol Cell Cardiol (2021) 157: 98-103.
- 567 doi:10.1016/j.yjmcc.2021.05.003

43. Heinrichs M, Ashour D, Siegel J, Buchner L, Wedekind G, Heinze KG, et al. The

- 569 healing myocardium mobilizes a distinct B-cell subset through a CXCL13-CXCR5-
- 570 dependent mechanism. Cardiovasc Res (2021) 117: 2664-76. doi:10.1093/cvr/cvab181
- 44. Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, et al. Temporal
- 572 dynamics of cardiac immune cell accumulation following acute myocardial infarction.

573 J Mol Cell Cardiol (2013) 62: 24-35. doi:10.1016/j.yjmcc.2013.04.023

- 45. Zhang M, Michael LH, Grosjean SA, Kelly RA, Carroll MC, Entman ML. The role
- of natural IgM in myocardial ischemia-reperfusion injury. J Mol Cell Cardiol (2006)
- 576 41: 62-67. doi:10.1016/j.yjmcc.2006.02.006
- 577 46. Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM, et
- al. Mechanisms of Autoantibody-Induced Pathology. Front Immunol (2017) 8: 603.
- 579 doi:10.3389/fimmu.2017.00603
- 47. Haudek SB, Trial J, Xia Y, Gupta D, Pilling D, Entman ML. Fc receptor
  engagement mediates differentiation of cardiac fibroblast precursor cells. Proc Natl
  Acad Sci U S A (2008) 105: 10179-84. doi:10.1073/pnas.0804910105
- 48. Cordero-Reyes AM, Youker KA, Torre-Amione G. The role of B-cells in heart
- 584 failure. Methodist Debakey Cardiovasc J (2013) 9: 15-19. doi:10.14797/mdcj-9-1-15
- 49. Ong S, Ligons DL, Barin JG, Wu L, Talor MV, Diny N, Fontes JA, Gebremariam
- 586 E, Kass DA, Rose NR, Čiháková D. Natural killer cells limit cardiac inflammation and
- fibrosis by halting eosinophil infiltration. Am J Pathol. 2015 Mar;185(3):847-61. doi:
- 588 10.1016/j.ajpath.2014.11.023.
- 50. Sobirin MA, Kinugawa S, Takahashi M, Fukushima A, Homma T, Ono T, Hirabayashi K, Suga T, Azalia P, Takada S, Taniguchi M, Nakayama T, Ishimori N, Iwabuchi K, Tsutsui H. Activation of natural killer T cells ameliorates postinfarct cardiac remodeling and failure in mice. Circ Res. 2012 Sep 28;111(8):1037-47. doi: 10.1161/CIRCRESAHA.112.270132.
- 594 51. Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martínez-Maza O, Gage 595 JR. Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy 596 in heart failure. Am J Cardiol. 2004 Apr 15;93(8):1007-11. doi:
- 597 10.1016/j.amjcard.2003.12.054.